Deucravacitinib治疗银屑病关节炎的2期试验:与疾病活动度、药效动力学及临床反应相关的生物标志物
这项2期试验将203例银屑病关节炎患者按1:1:1随机分配至安慰剂组、deucravacitinib 6 mg每日一次组或12 mg每日一次组。结果显示,deucravacitinib组中IL-23通路相关生物标志物(IL-17A、BD-2、IL-19)及CXCL9、CXCL10、C反应蛋白、基质金属蛋白酶3、4型胶原降解标志物水平在第16周较基线显著降低(P<0.01);基线IL-17A和BD-2水平高的患者PASI75反应率显著更高(比值比分别为15.76和15.41)。结论认为这些生物标志物可能预测deucravacitinib的治疗反应。
要点
- 基线IL-17A、BD-2、IL-19与PASI评分呈中度相关(r分别为0.4、0.56、0.5)。
- deucravacitinib组第16周IL-17A、BD-2、IL-19、CXCL9、CXCL10、CRP、MMP3及4型胶原降解标志物较基线显著降低(P<0.01)。
- 基线IL-17A高者PASI75比值比15.76、BD-2高者比值比15.41,均高于低水平者。
核心结论
- Deucravacitinib显著影响与Tyk2信号通路相关的关键炎症细胞因子(包括IL-23和I型干扰素)及胶原基质周转相关的生物标志物,这些生物标志物可能预测deucravacitinib的治疗反应。
研究设计与样本
- 2期试验(ClinicalTrials.gov标识符NCT03881059)将203例银屑病关节炎患者按1:1:1随机分配至安慰剂组、deucravacitinib 6 mg每日一次组或12 mg每日一次组。
- 通过免疫测定法检测与IL-23通路(IL-17A、β-防御素[BD-2]、IL-19)、I型干扰素通路、炎症及胶原基质周转相关的血清生物标志物,第16周评估临床反应(PASI75和ACR20)并评估血液学变量。
主要发现
- 基线时IL-17A、BD-2和IL-19与PASI评分呈中度相关(r分别为0.4、0.56和0.5)。
- 在deucravacitinib组中,第16周IL-17A、BD-2、IL-19、C-X-C基序配体9(CXCL9)、CXCL10、C反应蛋白、基质金属蛋白酶3和4型胶原降解标志物水平较基线显著降低(P<0.01)。
- 在deucravacitinib治疗患者中,较高的IL-23通路相关生物标志物水平预测较高的PASI75和ACR20反应率。
- 与基线IL-17A和BD-2低水平者相比,基线IL-17A高水平者(比值比15.76)和BD-2高水平者(比值比15.41)的PASI75反应率显著更高。
- 未观察到deucravacitinib引起JAK抑制特征的血液学变量变化。
关键数值与推荐
- 基线IL-17A与PASI评分相关r=0.4,BD-2相关r=0.56,IL-19相关r=0.5。
- deucravacitinib组第16周IL-17A、BD-2、IL-19、CXCL9、CXCL10、C反应蛋白、基质金属蛋白酶3和4型胶原降解标志物较基线显著降低(P<0.01)。
- 基线IL-17A高水平者PASI75比值比15.76,基线BD-2高水平者PASI75比值比15.41,均高于低水平者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our objective was to evaluate the association of serum biomarkers with baseline psoriatic arthritis (PsA) disease activity, pharmacodynamic effects of deucravacitinib on biomarker levels, and the relationship between biomarkers and clinical responses to deucravacitinib. METHODS: The phase 2 trial (ClinicalTrials.gov identifier: NCT03881059) randomly assigned 203 patients with PsA 1:1:1 to placebo, deucravacitinib at 6 mg once daily (QD), or deucravacitinib at 12 mg QD. Serum biomarkers associated with the interleukin 23 (IL-23) pathway (IL-17A, β-defensin [BD-2], and IL-19), type I interferon pathway, inflammation, and collagen matrix turnover were measured by immunoassay. Clinical responses (≥75% improvement from baseline in the Psoriasis Area and Severity Index [PASI75] and ≥20% improvement from baseline in American College of Rheumatology criteria [ACR20] responses) were measured at week 16. Hematologic variables were also assessed. RESULTS: IL-17A, BD-2, and IL-19 had a modest association with PASI scores (r = 0.4, r = 0.56, and r = 0.5, respectively) at baseline. In deucravacitinib groups, IL-17A, BD-2, IL-19, C-X-C motif ligand 9 (CXCL9), CXCL10, C-reactive protein, matrix metalloproteinase 3, and collagen type 4 degradation marker levels were significantly reduced at week 16 versus baseline (P < 0.01); higher levels of IL-23 pathway-associated biomarkers predicted higher PASI75 and ACR20 response rates in deucravacitinib-treated patients. Significantly higher PASI75 response rates were seen in patients with high baseline IL-17A (odds ratio 15.76) and BD-2 levels (odds ratio 15.41) versus low baseline IL-17A and BD-2 levels. Changes in hematologic variables that are characteristic of JAK inhibition were not observed with deucravacitinib. CONCLUSION: Deucravacitinib significantly impacted biomarkers associated with Tyk2 signaling pathways of key inflammatory cytokines, including IL-23 and type I interferon, and those related to collagen matrix turnover. These biomarkers may predict treatment responses to deucravacitinib.
引用
- FitzGerald O, Gladman DD, Mease PJ, et al. Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses. Arthritis Rheumatol. 2024. PMID: 38770592. doi:10.1002/art.42921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。